Six SSc skin fibroblast cell lines were treated with four low molecular antifibrotic compounds, including bardoxolone (Nrf2, a key transcription factor that regulates antioxidant activity, inducer: CDDO, 5mM), imatinib (a tyrosine kinase inhibitor: IM,10mM), rosiglitazone (PPARgamma agonist: Rosi,10mM), PGJ2 (PPARgamma agonist,10mM), or DMSO (control) for 24 h. This evidence concerns the gene PPARG and systemic sclerosis.